Addiction

Author Index, Volume 91, 1996

*Indicates a Book Reviewer
S indicates Supplement issue (December)

Abdel-Mawgoud, M., 1859
Acuda, S. W., 807
Adèr, H. J., 711
Adams, I. B., 1585
Adams, V., 1489
Adlaf, E., 504
Al-Haddad, M. K., 1859
Allamani, A., 228
Allen, J., S3, S51
Alterman, A. I., 535
Ames, G., 829, 1041
Amundsen, A., 1821
Anda, R. F., 113
Anderson, P., 25, 275, 477, 749, 896
Annis, H. M., 1101, 1127, 1804
Anthony, J. C., 523, 583, 1731
Arminger, G., 1335
Ashley, M. J., 1615

Babor, T. F., 5, 477, 859, 1757, 1877
Baker, A., 1115
Balfour, D., 953
Ball, A., 1095
Ball, J. C., 151*
Ball, S. A., 1882*
Banerjee, G., 145
Barbarini, G., 263
Barclay, L., 1715
Batel, P., 221
Batlle, E., 549
Bauman, K. E., 185
Beebe, T. J., 687
Bell, N., 1007
Bell, R. M., 1489
Bennett, L. A., 199, 229
Benowitz, N., 129
Berg, J. E., 1884*
Berry, C., 1271, 1290
Berzlanovich, A., 1479
Bi, X., 1675
Blume, S. B., 473
Boixet, M., 549
Bolibar, I., 549
Bondy, S., 31, 643, 1439, 1615, 1663
Bono, G., 263
Borg, L., 1687
Bourgault, C., 1505
Boyle, R. G., 1553*
Breslau, N., 583
Breslin, C., 1359
Brett, P. J., 1127
Bretteville-Jensen, A. L., 63
Brooke, D., 317
Brugal, M. T., 419
Buchan, G., 1359
Bucholz, K. K., 1469

Cacciola, J. S., 535
Caetano, R., 577, 1427, 1453
Calsyn, D. A., 1197
Carbonneau, R., 1161
Casswell, S., 26, 477
Castellani, B., 1556*
Caulkins, J., 1261
Chafetz, M. E., 1875
Chalmers, C., 1457
Chalmers, D., 985
Chen, C. N., 1375
Cheng, H., 1675
Chermack, S. T., 1235*
Chou, J. Z., 1687
Chowdhury, A. N., 145, 766
Clee, W. B., 1390
Collins, E., 1115
Collins, L. M., S197
Connors, G. J., S5, S51, S89, S121, S173, S191, S241
Cooke, K. R., 1865
Cooke, M., 1115, 1715
Copeland, J., 1141
Crabbe, T., 1547
Crofts, N., 181, 1187

Darke, S., 81, 405, 413, 1727, 1765
Davis, P. E., 1365
Dawson, D., 1623, 1831
De Iceta, M., 1179
Deery, H. A., 815
Degwitz, P., 890*
Demers, A., 1505
Des Jarlais, D. C., 1089
Detels, R., 1675
DeVillaer, M., 701
Doan, K., 1293
Dobkin, P. L., 1161
Dolan, K., 917
Doll, R., 32
Dong, L., 1675
Donmall, M., 1547
Donoghoe, M. C., 1457
Donovan, D. M., S5, S29, S129
Drop, M. J., 357
Drummond, C., 958
Duan, S., 1675
Dubois, G., 1870
Duffy, F. F., 523, 1731
Dunn, J., 1094
Dunt, D., 295

Edelman, R. J., 1365
Edwards, G., 5, 15, 151*, 459, 477, 905, 1757, 1877
Eide, A. H., 807
Ellikson, P. L., 1489
Elwood, C., 1705
Endicott, J., 1517
Ennet, S. T., 185
Erickson, P. G., 1236*
Escobedo, L. G., 113
Everitt, B., 951

Fanslow, J., 985
Farkas, A. J., 1271, 1290

Farrell, M., 321
Farrington, D. P., 498
Fea, M., 263
Feehan, M., 1865
Fergusson, D. M., 483, 506
Ferrence, R., 477, 1615
Ferris, J., 643
Ferry, D., 1705
Feuerlein, W., 1807
Fibiger, H. C., 954
Fillmore, K. M., 1449, 1872
Finney, J., 442*
Finney, J. W., 787, 1773, 1813
Fischer, G., 1479
Fisher, E. B., 1285
Flaherty, J. A., 391
Fleming, C., 1197
Fleming, J., 1325
Forster, J. L., 589
Forsyth, A. J. M., 511
Foulds, J., 1389
Franzon, M., 1293
Fuchs, W. J., 1236*
Fulkerson, J. A., 687

Garrard, J., 295
Ghodse, H., 764
Giesbrecht, N, 477, 504, 1615
Gilpin, E. A., 1271
Godfrey, C., 477
Goldberg, S. R., 957
Gossop, M., 153*
Graham, K., 1127
Greenfield, T. K., 557, 1427, 1453
Griffiths, P., 321
Grube, J. W., 845, 1843
Gruenewald, P. J., 967, 1637
Gureje, O., 1529
Gurney, J. G., 255

Hagedorn, J. M., 1883*
Hahn, A. C., 1773
Hall, W., 81, 405, 413, 439*, 759, 770, 917, 1141, 1727, 1808
Hammer, T., 1345
Hando, J., 81
Harford, T., 1444
Harris, R. J., S155
Harrison, K., 1699
Harrison, L. D., 47
Harrison, P. A., 687
Hasin, D., 1517
Hawks, D., 769, 1869
Hawthorne, G., 288, 295, 1151
Hay, ⅄. W. M., 1699
Hays, R. D., 1489
Heather, N., 469, 1115
Hedeker, D., S209
Heeren, T., 1007
Hek, H. van der, 711
Helzer, J. E., 223
Henningfield, J., 129
Hepple, J., 269
Herd, D., 845
Hirschl, M. M., 1479
Ho Kong Wai, B., 435
Ho, A., 1687
Holder, H. D., 477
Homel, R., 1231*
Horwood, L. J., 483, 506
Howland, J., 1007
Huang, S., 1675
Hughes, J. R., 1284, 1797
Hunt, K., 243
Hunter, G. M., 1457
Hurt, R. D., 441*

Jackson, T. R., 1197
James Baker, P., 879
Janca, A., 199, 229, 1529
Jarvis, M. J., 427
Jia, M., 1675
Johanson, C-E., 523, 1731
Johnson, E. O., 583
Johnstone, B. M., 1449
Jolley, D., 1187
Jones, B. T., 89
Jurkovich, J., 255

Kadden, R. M., 859, S139
Kalant, H., 762
Kalmijn, J. A., 1469
Kaplan, R. M., 1271, 1290
Kaskutas, L. A., 1555*
Kavanagh, D. J., 345, 1539
Kennedy, N. J., 47
Kerimi, N., 775
Kielhorn, F-W., 121
Kirch, D. G., 113
Klee, L., 829
Klingemann, H. K. H., 502, 723
Kranzler, H. R., 859
Kreek, M. J., 1687
Küfner, H., 1807
Kuhlthau, K., 1007
Kvalen, I. L., 985
Kwan, E., 1359

Laggner, A., 1479
Lam, L. C. W., 1375
Langley, J., 985
Laranjeira, R., 1094, 1870
Lee, D. T. S., 1375
Lee, M., 1007
Lemmens, P. H., 357, 477, 1445
Lemon, J., 759
Levine, S., 1007
Lewinsohn, P. M., 375
Li, Q., 1517
Li, Z., 1675
Lindström, L., 1812
Longabaugh, R., 1809, S51, S73, S99, S111, S191, S241
Louie, R., 1187
Love, A. W., 815
Lowman, C., S3, S51, S73
Loxley, W., 1552*
Lucas, P., 1388
Lundberg, M., 1307
Lynskey, M. Y., 483, 506, 889*
Lyons Wall, P. M., 1053

Maisto, S. A., S5, S51, S89, S121, S173, S241
Mäkelä, K., 477, 885*, 1447
Mäkelä, P., 101
Mangione, T. W., 1007
Marlatt, G. A., S37, S145, S231, S241
Marsh, A., 1885*
Martínez-Cano, H., 1179
Martínez-Gras, I., 1179
Martin, B. R., 1585
Martin, G., 671
Martin, R. A., S197
Mattick, R. P., 1715, 1727
Mauri, M., 263
McBride, A. J., 1390
McClelland, M., 1705

McCloud, S., 1517
McGee, R., 1865
McGuigan, K. A., 1489
McKay, J. R., 535, 1803
McKeganey, N., 1092
McMahon, J., 89
Mermelstein, R. J., S211
Midanik, L. T., 477, 557, 1233*, 1427, 1453
Millar, A. B., 967
Miller, W. R., 779, S3, S15, S51, S155, S191, S231, S241
Minoli, L., 263
Mitchell, P. R., 1637
Mody, F. V., 1293
Monahan, S. C., 787
Moos, R. H., 1773, 1813
Moser, A. E., 1101
Mosher, J. F., 1871
Mullen, K., 243
Muller, A., 231
Murakami, A., 1365
Murray, D. M., 589
Myles, J., 443*

Neelman, J., 321
Negrete, J. C., 767
Neve, R. J. M., 357
Newcome, R., 1728
Newhouse, P., 129
Nico Plomp, H., 711
Nicolaides, B. M., 1211
Nilssen, O., 255
Nilsson, F., 1293
Noble, A., 1457
Norström, T., 329, 477

Olmstead, R., 1293
O'Neill, K., 1115
Österberg, E., 477

Pape, H., 1345
Parry, J., 1457
Partanen, J., 225
Pedersen, W., 565
Perkins, K. A., 129
Peters, J. E., 1687
Pierce, J. P., 1271, 1290
Pomalima, R., 1179
Pomerleau, O., 129
Ponicki, W. R., 967
Porter, R., 885*
Power, R., 146
Prochaska, J. O., 1281

Quarrie, K. L., 1865

Raistrick, D., 1699
Rawlins, J. N. P., 869
Rehm, J., 31, 275, 440*, 896, 1335, 1439, 1615
Reid, K., 1687
Reissman, F., 886*
Reuter, P., 1261
Rhodes, T., 753, 1457
Ricciardelli, L. A., 1031
Richman, J. A., 391
Richmond, R., 35
Ries, R., 255
Rivara, F. P., 255
Robbins, T., 951
Robson, P., 269
Roeper, P., 967
Rohde, P., 375
Romelsjö, A., 477, 1307
Room, R., 31, 199, 229, 275, 477, 643, 896, 1441, 1615
Rosbrook, B., 1271
Rosenthal, D., 1187
Rospenda, K. M., 391
Ross, H. E., 440*
Ross, J., 81, 405, 413
Rossow, I., 1413, 1651, 1821
Rounsaville, B. J., 859
Ruben, S. M., 285
Rubin, A., S51, S73, S99, S111, S241
Rush, B., 629, 671
Rutherford, M. J., 535
Rutter, M., 495
Ryan, C. F., 39
Ryan, R. M., 1555*
Ryder, D., 603, 1265

Saloojee, Y., 149*
Saltz, R., 829, 1041
Samarasinghe, D., 1810
Sanchez-Craig, M., 779
Sartorius, N., 199, 229
Saxena, S., 222
Saxon, A. J., 1197
Sayer, G. P., 345, 1539
Schindler, C. W., 957
Schmid, R., 1479
Schmidt, C., 829
Schmidt, L., 199, 229, 657
Schneider, N. G., 1293
Schuckit, M. A., 1469
Scurlock, H., 1388
Seeley, J. R., 375
Seidler, D., 1479
Selwyn, P. A., 11
Shaper, A. G., 29
Shepherd, J., 501
Shiffman, S., 1289
Short, B. J., 589
Shum, P. P. S., 1375
Sikdar, S., 285
Silva, P. A., 1705
Simpura, J., 477
Sinforiani, E., 263
Singh, S., 435
Single, E., 1615
Sitharthan, T., 345, 1539
Skog, O-J., 325, 477
Skretting, A., 1234*
Skrondal, A., 565
Smart, R., 152*
Smith, T. L., 1469
Sobell, L. C., 1359
Sobell, M. B., 1359
Sobrino, M. P., 1179
Solowij, N., 759, 770
Spak, F., 888*
Stanton, W. R., 1705
Stauffacher, M., 1553*
Stewart, J., 955
Stimson, G. V., 1085, 1098, 1457
Stockwell, T., 5, 1283, 1757, 1877
Stout, R. L., S51, S73, S99, S111, S241
Strang, J., 321
Stuhlinger, G. H., 1479
Sullivan, G., 1390
Sutton, M., 63
Sutton, S., 1287
Suzuki, K., 888*
Swan, G., 129
Swift, W., 1141
Swinkels, H., 357

Tam, T. W., 557, 657, 1427, 1453

Tennen, H., 859
Tipp, J. E., 1469
Tómasson, K., 1019
Tongue, E., 1063
Tonigan, J. S., S155
Toomey, T. L., 589
Torgerud, C. R., 687
Toribio, A., 419
Torralba, L., 419
Tortosa, M. T., 419
Traeen, B., 995
Tremblay, R. E., 1161
Treno, A. J., 967, 1637
Turner, T. B., 1876
Tyas, S., 671

Uzych, L., 1387

Vaglum, P., 1019
Vail, A., 1699
Valverde, J. L., 419
Varma, S. L., 435
Vazquez-Barquero, J. L., 1529
Vela-Bueno, A., 1179
Velicer, W. F., 1281, S197
Venesoen, P., 1127
Villalbí, J. R., 419
Vitaro, F., 1161
Voas, R. B., 1843

Wagenaar, A. C., 589
Waldron, D., S51, S241
Wallace, S., 287
Waller, A. E., 1865
Walsh, T., 879
Ward, J., 1727
Watts, D., 150*
Webster, I., 1053
Weisner, C., 657
Wellman, N. A., 869
Wells, E. A., 1197
Welshman, J., 1379
Welte, J. W., 1881*
West, R., 1757
Westerberg, V. S., S51, S121, S155, S241
White, J. M., 39
White, N. M., 921, 960
Wiesbeck, G. A., 1469
Wilhelmsen, B. U., 1883*
Williams, J. H., 869
Williams, R., 243
Williams, R. J., 1031
Williams, S., 1865
Wodak, A., 181, 1090, 1115, 1551*
Woisetschlaeger, C., 1479
Wolff, K., 1699
Wolfson, M., 589
Woody, G. E., 226
Wu, Z., 1675

Yang, Z., 967

Zacny, J. P., 1581
Zador, D., 1053, 1765
Zeldman, A., 1555*
Zhang, J., 1675
Zhu, S-H., 1271, 1290
Zywiak, W. H., S51, S73, S89, S121, S173, S241

Addiction

Subject Index, Volume 91, 1996

The following abbreviations have been used in this index:
Ed Editorial
L Letter
* Book review
# News and Notes
S Supplement issue (December)

Addiction, 153*, 442*, 890*, 1236*
  behaviour change, 921–949, 951–965
  clinical depression during recovery, 1882*
  conferences, 129–144, 606–607#, 1615–1674
  dual diagnosis, 859–868, 1019–1034(L), 1555*
  historical aspects, 885*
  Internet web page, 894#
  and psychotherapy, 1885*
  publications, 15–16(Ed), 156–157#, 294#, 445#, 1066#, 1239–1240#, 1560#, 1736#
  and relapse, 535–548, 1127–1139, S3–S42
  research, 5–9(Ed), 146–147(L), 294#, 921–949, 951–965, 1392#, 1417–1425
    ethical standards, 5–9(Ed), 1063–1064(L), 1869–1879(L)
  training, 893–894#
  treatment systems, 629–736, 1417–1425
Addiction, editorial review process, 1757–1763(Ed)
Addiction Biology, 15–16(Ed)
Adolescents
  alcohol
    and aggression, 1235*
    and crime, 483–494, 495–510
    consumption changes over time, 1345–1357
    cultural orientation and drinking, 807–814
    purchase and outlet policies, 589–602
    predicting drink-driving behaviours, 1843–1857
    and sex, 995–1006
    use and abuse, 375–390, 1489–1503
  Antenna research project into addiction, 1392#
  drugs
    determinants of use, 523–534 + 1731–1733 (erratum)
    and peer influences, 185–198
  gambling, 1556*
  smoking and quitting, 1705–1714
  substance abuse, 150*
    school-based prevention, 888*, 889*, 1885*
    see also Young people
AIDS/HIV infection
  drug injectors,
    in Amsterdam, 1552*
    cognitive disorders, 263–268
    contact tracing, 917–919(Ed)
    interventions, 1085–1088(Ed), 1089–1099, 1115–1123, 1552*
    risk behaviour, 157#, 1085–1088(Ed), 1089–1099, 1115–1125
    sterile needles and bleach, 1551*
    treatment, 11–13(Ed)
    women, 435–438
Alcohol
  consumption, 1234*, 1615–1674
    adolescents, 375–390, 483–494, 495–510, 589–602, 807, 814, 995–1006, 1235*, 1345–1357, 1489–1503
    and aging, 1881*
    Australia, 1325–1334
    and availability, 1231*
    and black identity, 845–857
    brief interventions, 345–355
    controlled drinking, 603–604(L)
    and crime, 483–494, 495–510, 985–993
    dose-harm relationship, 325–337
    drinking patterns, 1615–1674

Alcohol—consumption (*cont*)
and driving *see* Drink-driving
and ethnic identity, 845–857
Europe, 275–283 + 896 (erratum)
expectancies and dependence symptoms, 1031–1039
Finland, 101–112
gender differences, 357–373, 829–844, 1041–1051, 1831–1842
and health-related problems *see* Alcohol problems
Irish peoples', 243–254
moderation, 345–355, 440*, 477–481, 775–778, 603–604(L)
mortality, 325–337, 339–344, 1821–1829
New Zealand rugby players, 1865–1868
in pregnancy, 473–475(Ed)
problems *see* Alcohol problems
sensible drinking guidelines, 25–33 + 608 (erratum)
sexual risk behaviour, 995–1006
and sexual victimization, 565–581
and social class, 1307–1323, 1821–1829
social pharmacology, 753–758(Ed), 1615–1674
solitary drinking, 1505–1516
and suicide, 101–112, 1413–1416(Ed)
Switzerland, 1335–1344
temporal drinking patterns, 1623–1636
US *see* United States
variation by work-site, 1007–1017
and violence, 1651–1662
women *see* Women
and workplace problems, 391–403, 1427–1437, 1439–1456
young people, 1345–1357
Zimbabwe, 807–814
dependence
dose-risk factors, 1427–1437, 1439–1456
DSM and ICD-10 diagnoses, 1517–1527
and expectancies, 1031–1039
risks by gender, 1831–1842
see also Alcoholism
education, 888*, 889*, 1233*, 1883*
history: women and US law, 1211–1229
industry and research funding, 5–9(Ed), 1063–1064(L), 1869–1879(L)
policies, 35–37, 477–481, 775–778, 1265–1270
developing countries, 1736#
Europe, 275–283 + 896 (erratum), 749–752(Ed)
protective effect debate, 325–337, 440*
Turkmenistan, 775–778
UK, 25–33 + 608 (erratum)
problems, 1615–1674
and aging, 1881*
dose-risk relationship, 25–33 + 608 (erratum), 325–337, 440*, 1427–1437, 1439–1456
J-curve and public health, 325–337
predictors, 1307–1323
prevention, 603–604(L)
and psychiatric disorders, 1019–1030, 1884*
screening test in trauma patients, 255–262
research, 1615–1674
Albert Tuyns, 17–23
assessing use, 1663–1674
centres, 294#
cross-cultural diagnosis, 199–220, 221–230, 1529–1538
industry supported, 5–9(Ed), 1063–1064(L), 1869–1879(L)
measures of drinking problems, 829–844, 1041–1057
quantitative/qualitative, 146–147(L)
risk functions, 1427–1437, 1439–1456
selection bias in surveys, 557–564
treatment outcome, 469–472(Ed), 779–785, 787–805
treatment systems, 629–736, 1773–1796, 1803–1820
workplace studies, 391–403
see also Relapse research *and* Research methods
Alcohol Policy in Developing Societies project, 1736#
Alcohol Policy and the Public Good, 477–481, 775–778
Alcoholism, 890*
and aging, 1881*
in Asia, 440*
children of alcoholics *see* Children of alcoholics
diagnoses, S15–S27
among doctors, 317–319(Ed)
DSM and ICD-10 diagnoses, 1517–1527
in Europe, 440*
history, Brühl-Cramer, 121–128
among lawyers, 1391–1392#
mortality and social class, 1821–1929
and psychiatric disorders, 859–868, 1019–1030, 1555*
stages of change seminar, 606–607#

Alcoholism (*cont*)
treatment, 1555*
aftercare telephone contact, 1359–1364
client monitoring system, 701–709
by correspondence, 1539–1545
determinants of suggestions for help, 643–655
in different community services, 657–669
history, 885*
inpatient vs outpatient, 1773–1796, 1803–1820
inter-agency needs assessment, 701–709
Ontario's use of US programs, 671–685
outcome
monitoring, 687–699, 779–785, 787–805, 1773–1796, 1803–1820, S15–S27
and polydrug outcome patterns, S15–27
predictors, 89–99, 1539–1545
research, 469–472(Ed)
role of coping in relapse, 1101–1114
relapse *see* Relapse
self-help, 886*, 1391–1392#
systems model, 629–736
in US, 440*
and women, 151*
Amphetamine abuse, route and symptoms, 81–87
Amsterdam,
HIV in drug users, 1553*
methadone dispensing circuit, 711–721
Antenna research project, 1392#
Asia, alcoholism, 440*
Australia
alcohol licensing, 1231*
amphetamine abuse, 81–87
cannabis use effects, 759–773
early intervention programmes, 1151–1159
heroin overdose, 405–411, 413–417
women
alcohol/drug problems, 1141–1150
drinking survey, 1325–1334
Austria, drugs overdose survey, 1479–1487

Bahrain, treatment of heroin addiction, 1859–1864
Ball, John, interview, 1417–1425
Barcelona
cocaine abuse, 1236*
drug-related deaths, 419–426
see also Spain
Benzodiazepines,
dependence types, 1179–1186
GPs' prescribing habits, 549–556
Brain
addictive drugs as reinforcers, 921–949, 951–965
cognitive function and medical drugs, 1581–1584(Ed)
Brazil
drug injectors and HIV, 1094–1095
industry-funded research, 1870–1871 (L)
British Medical Association, Guidelines on Sensible Drinking, 25–33 + 608 (erratum)
Brühl-Cramer and alcoholism, 121–128
Buprenorphine, 443*
withdrawal and koro, 145–146(L)

Caffeine and cue exposure in ex-smokers, 269–273
Cancer and alcohol consumption, 17–23
Cannabis
effects, 759–773
pharmacology and toxicology, 1585–1614
and schizotypy, 869–877
withdrawal syndrome, 1469–1477
Children
Children in Europe report, 1559#
with fetal alcohol syndrome, 473–475 (Ed)
primary school-based intervention, 1151–1159
and smoking cessation by parents, 427–434
see also Adolescents
Children of alcoholics, characteristics of sons, 1161–1177
China, risks of drug use, 1675–1686
Cigarettes *see* Smoking
Cocaine abuse
in Barcelona, 1236*
quantitative analysis of urinary levels, 1687–1698
relapse interview, 535–548
Cough mixture misuse, 1375–1378
Crime
and alcohol, 985–993
and drugs, 63–79, 893#, 1261–1264(Ed)
interrogative suggestibility in drug users, 1365–1373
Cyclopyrrolones abuse, 285–286(L)
Czech Republic, news, 293–294#

Dance drug users in Glasgow, 511–521
Developing countries
alcohol policies, 1736#
industry-funded research, 1870–1871(L)

Doctors
substance abuse, 317–319(Ed)
problem drinking and workplace harassment, 391–403
Drink-driving, 1239–1240#
and alcohol availability, 967–983
dose-risk, 1427–1437, 1439–1456
and drinking patterns, 1637–1650
hazard perception, 815–827
predicting underage behaviours, 1843–1857
Driving and medical drugs, 1581–1584(Ed)
Drugs
education, 286–291(L), 888*, 889*, 1883*, 1885*
medical use and driving/working, 1581–1584(Ed)
misuse, 890*
adolescents, 185–198, 523–534 + 1731–1733 (erratum)
community strategies, 1883*
and crime, 63–79, 893#, 1261–1264(Ed)
Czech Republic, 293–294#
at dance events, 511–521
by doctors, 317–319(Ed)
drugs as reinforcers, 921–949, 951–965
history, 885*
initiation risk factors, 1675–1686
initiation into injection, 1187–1196
injecting behaviour and AIDS/HIV
in Amsterdam, 1552*
contact tracing, 917–919(Ed)
interventions, 1085–1088(Ed), 1089–1099, 1115–1125, 1552*
mortality rate, 1765–1772
risk behaviour, 157#, 1085–1088(Ed), 1089–1099, 1115–1125
sterile needles and bleach, 1551*
women, 435–438
injectors
and hepatitis B, 1457–1467
and hepatitis C, 181–184(Ed)
income generation, 63–79
initiation, 1187–1196
and interrogative suggestibility, 1365–1373
maturing out, 152*
Mexico, 47–61
mortality, 419–426
overdose, 1479–1487
and prices, 1261–1264(Ed)
and prostitution, 63–79
and psychiatric disorders, 859–868, 1555*
sedatives, 285–286(L), 1389–1390(L)
social pharmacology, 753–758(Ed)
suicide and overdose, 321–323(Ed)
UK *see* United Kingdom
US *see* United States
women *see* Women
psychomotive/cognitive functioning, 1581–1584(Ed)
research, 1417–1425
centres, 294#
cross-cultural diagnosis, 199–220, 221–230, 1529–1538
quantitative/qualitative, 146–147(L)
systems model, 629–736
treatment, 439*, 1417–1425, 1555*
client monitoring systems, 710–709
inter-agency needs assessment, 701–709
and medical care needs, 11–13(Ed), 39–45
methadone *see* Methadone
Ontario's use of US programs, 671–685
outcome monitoring, 687–699, 1392#
self-help, 886*
Switzerland, 723–736
systems model, 629–736
see also Relapse
see also specific drugs
Drugs Misuse Database, Manchester, 1547–1550
Drunkenness, habitual *see* Alcoholism
DSM and ICD-10 alcohol diagnoses, 1517–1527
DSM-III-R
nicotine dependence, 583–588
structured clinical interview in substance abuse, 859–868
Dual diagnosis patients' drinking, 1019–1030

Education and training
European Addiction Training Institute, 893–894#
of social workers in alcohol problems, 1233*
Egypt, news, 1560#
Emergency room studies, 1479–1487
Employees' drinking across work-sites, 1007–1017
Ethanol *see* Alcohol
Europe
alcohol policies, 275–283 + 896 (erratum), 749–752(Ed)
alcoholism, 440*
report on children, 1559#

European Addiction Training Institute, 893–894#
European Charter on Alcohol, 749–752(Ed)

Fetal alcohol syndrome, 473–475(Ed)
Finland and suicide, 101–112
France and alcohol
  and advertising, 1870(L)
  and mortality, 339–344, 1873–1958

Gambling, by adolescents, 1556*
General practice, benzodiazepines prescribing patterns, 549–556
Glasgow
  drug use at dance events, 511–521
  see also Scotland
Great Britain *see* United Kingdom
Greece, diagnostic criteria of substance abuse, 199–220, 221–230, 1529–1538

Health Education *see* Public health education
Hepatitis B in drug injectors, 1457–1467
Hepatitis C in drug injectors, 181–184(Ed)
Heroin addiction
  and AIDS, 439*
  Amsterdam's methadone dispensing circuit, 711–721
  fatal overdose, 1765–1772
  non-fatal overdose, 405–411, 413–417
  treatment in Bahrain, 1859–1864
  UK policies, 151*
History of relapse research, S37–S49
HIV infection see AIDS/HIV infection
Holland *see* Netherlands
Hong Kong, cough mixture abuse, 1375–1378
Hospitals, emergency room studies, 1479–1487

ICD-10 and DSM alcohol diagnoses, 1517–1527
India, diagnostic criteria of substance abuse, 199–220, 221–230, 1529–1538
International Council on Alcohol and Addictions, ethical standards, 1063–1064(L)
Internet, substance abuse site, 894#
Interviews
  Albert Tuyns, 17–23
  John Ball, 1417–1425
Irish descent, religion and alcohol/tobacco use, 243–254

Keller, Mark, obituary, 905–906
Kettil Bruun Society meeting, 629–642(Ed)
Korea *see* South Korea

Koro in buprenorphine withdrawal, 145–146(L)

Marijuana *see* Cannabis
Marlatt's relapse taxonomy *see* Relapse
Methadone maintenance
  Amsterdam's dispensing circuit, 711–721
  health status at entry, 39–45
  and polydrug use, 1699–1704
  predictors of outcome, 1197–1209
  safety, 1727–1730(L)
  treatment outcome, 1417–1425
  women's high sugar intake, 1053–1061
Mexico
  diagnostic criteria of substance abuse, 199–220, 221–230, 1529–1530
  drug use, 47–61

National Treatment Outcome Research Study, UK, 1392#
Netherlands,
  drug users' income, 63–79
  gender differences in drinking behaviour, 357–373
  see also Amsterdam
New Zealand and alcohol
  assaults near licensed premises, 985–993
  juveniles and delinquency, 483–494, 495–510
  rugby players' drinking patterns, 1865–1868
Nicotine
  conferences, 129–144, 156#
  dependence, 441*
    DSM-III-R dimensionality, 583–588
  replacement treatments
    efficacy of inhaler, 1293–1306
    and psychosis, 1388–1389(L)
  research, 129–144, 156–157#
Norway
  alcohol
    adolescents and sex, 995–1006
    and sexual victimization, 565–581
  drug users' income, 63–71
Nigeria, diagnostic criteria of substance abuse, 199–220, 221–230, 1529–1538

Obituary
  Mark Keller, 905–906
  H.B. Spear, 459
Ontario's use of US drug programs, 671–685
Opiates *see* Drugs *and specific opiates*
Opioids and psychomotor/cognitive functioning, 1581–1584(Ed)

Physicians *see* Doctors *and* General practice
Prisoners and addiction, 1065–1066#
Problem drinking *see* Alcoholism
Prussia, alcohol and mortality 1875–1918, 339–344
Psychiatric disorders and addiction, 859–868, 1019–1030, 1555*
Psychotherapy and addiction, 1885*
Public health education
  alcohol, 35–37, 325–337, 477–481, 749–752(Ed), 775–778
  injectors and hepatitis, 181–184(Ed), 1457–1461
  injectors and HIV, 1085–1088(Ed). 1089–1099, 1115–1125
  prevention approaches, 286–291(L), 603–604(L), 1151–1159, 1265–1270, 1883*
  school based, 888*, 889*
  smoking, 149*

Questionnaires
  alcohol relapse interview, S231–S240
  cocaine relapse interview, 535–548
  measures of women's drinking problems, 829–844, 1041–1051
  reasons for drinking, S121–S130
  SF-36 health survey at methadone entry, 39–45

Relapse, S3–S244
  assessment issues, S29–S36
  bias in recall of relapse events, S29–S36
  coping skills, S37–S49
  definitions, S5–S13, S15–S27, S29–S36
  individual vs group training, 1127–1139
  interview, intake and follow-up, S231–S240
  Marlatt's taxonomy of high risk situations, S37–S49
    extensions beyond high risk situations
      post-treatment functioning of alcoholics, S173–S189
      relapse antecedents, S155–S171
    replication and extension projects, S51–S196
      alternative questionnaire on reasons for drinking, S121–S130
      amended scoring rules, S241–S244
      commentaries, S131–S153
      construct validity, S89–S97
      gender differences, S111–S120
      multidimensional rating system, S99–S110
      overview, S53–S72
      predictive validity, S99–S110
      reliability, S73–S88
      validity of taxonomic categories, S121–S130
    models, S5–S13, S15–S27, S29–S36, S37–S49, S173–S189
    research
      alcohol-related variables, S15–S27
      determinants, S29–S36
      future directions, S5–S13, S129–S153, S191–S196
      history, S37–S49
      latent transition analysis, S197–S209
      random-effects regression models, S211–S229
Relapse Replication and Extension Project, S51–S196
Research methods
  attributors in drugs misuse database, 1547–1550
  cross-cultural diagnostic issues, 199–220, 221–230, 1529–1538
  latent transition analysis for longitudinal data, S196–S209
  precipitants of relapse, S3–S244
  quantitative/qualitative, 146–147(L)
  random-effects regression models in relapse research, S211–S229
  replication studies of relapse taxonomy, S51–S196
  risk functions for alcohol problems, 1427–1437, 1439–1456
  selection bias in national surveys, 557–564
  social impact of interventions, 1151–1159
  treatment outcome, 779–785, 787–805
  treatment settings, 1773–1796, 1803–1820
  see also Alcohol research *and* Drugs research
Risk behaviour
  of drug injectors, 157#, 181–184(Ed), 435–438, 1085–1088(Ed), 1089–1099, 1115–1125, 1457–1467
  interventions, 1552*
  social pharmacology, 753–758(Ed)
  of young people, 995–1006, 1843–1857
Road accidents, alcohol-related *see* Drink-driving
Romania, diagnostic criteria of substance abuse, 199–220, 221–230, 1529–1538

School-based prevention programmes, 1151–1159
Scotland
  drug use at dance events, 511–521

drug users' income, 63–79
Sedatives abuse, 285–286(L), 1389–1390(L)
Self-help organization, 886*
Sexual behaviour
and alcohol consumption, 995–1006
social pharmacology, 753–758(Ed)
SF-36 health survey questionnaire, 39–45
Smoking
abstinence and caffeine, 269–273
adolescents, 1705–1714
cessation
addiction vs stages of change as predictors, 1271–1280, 1281–1292
brief interventions by midwives, 1715–1726
cost effectiveness, 149*
efficacy of nicotine inhaler, 1293–1306
by parents, 427–434
therapies in US, 1797–1802
history: juvenile smoking 1880–1914, 1379–1386
initiation and depression, 113–119
by Irish peoples, 243–254
passive, 1388(L)
self-reports, 1705–1714
switching to smokeless tobacco, 1554*
and visual temporal order, 879–884
see also Nicotine *and* Tobacco
Social and Health Effects of Different Drinking Patterns conference, 1615–1674
Social workers, training in alcohol problems, 1233*
Society for Research on Nicotine and Tobacco, 129–144, 156–157#
South Korea, diagnostic criteria of substance abuse, 199–220, 221–230, 1529–1538
Spain
benzodiazepine prescribing patterns, 549–556
cocaine abuse, 1236*
diagnostic criteria of substance abuse, 199–220, 221–230, 1529–1538
drug-related deaths, 419–426
Spear, H.B., obituary, 459
Suicide
and alcohol, 101–112, 1413–1416(Ed)
and overdose by drug users, 321–323(Ed)
Sweden, social class and drinking, 1307–1323
Switzerland
alcohol consumption, 1335–1344
drugs treatment, 723–736

Teenagers *see* Adolescents
Temazepam abuse, 157#
Tobacco
conference summary, 129–144
dependence *see* Nicotine addiction
litigation, 1388(L)
public health policies, 1265–1270
research, 129–144, 156–157#
see also Nicotine *and* Smoking
Traffic accidents, alcohol-related *see* Drink-driving
Training *see* Education and training
Turkey, diagnostic criteria of substance abuse, 199–220, 221–230, 1529–1538
Turkmenistan, alcohol policies, 775–778
Tuyns, Albert, interview, 17–23

United Kingdom
alcohol
misuse among lawyers, 1391–1392#
sensible drinking guidelines, 25–33 + 608 (erratum)
drugs
Crackdown on Drugs campaign, 1240#
Crimestoppers campaign, 893#
Drugs Misuse database, 1547–1550
heroin abuse policies, 151*
injectors and hepatitis, 181–184(Ed), 1457–1467
injectors and HIV, 1085–1088(Ed), 1089–1099, 1115–1125, 1552*
National Treatment Outcome Research Study, 1392#
prisoners and addiction, 1065–1066#
smoking interventions, 149*
see also Scotland *and* Wales
United States
alcohol
black identity and drinking, 845–857
changes in consumption 1950–1992, 231–242
NIAAA's relapse project, S51–S194
research and industry funding, 1871–1875(L)
risk functions for alcohol problems, 1427–1437, 1439–1456
teenage misuse, 1489–1503
treatment systems, 657–669
women
drinking problems, 829–844, 1041–1051
and the law 1850–1980, 1211–1229
alcoholism, 440*
diagnostic criteria of substance abuse, 199–220, 221–230, 1529–1538

drugs
history, 885*
trafficking and use, 47–61
Minnesota's treatment outcome monitoring, 687–699
National Clearing House for Alcohol and Drug Information, 1560#
Relapse Replication and Extension Project, S51–S196
smoking
cessation therapies, 1797–1802
initiation by Latinos, 113–119

Vienna, drug overdose survey, 1479–1487

Working and medical drugs, 1581–1584(Ed)
World Health Organization, 1560#
alcohol consumption, Europe, 275–283 + 896 (erratum)
cross-cultural diagnostic issues, 199–220, 221–230, 1529–1538
drug injectors and HIV, 157#
European research centres, 294#
Programme on Substance Abuse, 1066#
reorganization, 1735#
substance abuse treatment, 445#
Women
alcohol, 151*
Australian drinking survey, 1325–1334
consumption and sexual victimization, 565–581
fetal alcohol syndrome, 473–475(Ed)
functionality, 888*
gender differences in consumption, 357–373
indicators of problems, 829–844, 1041–1051
relapse risks, S111–S120
risks of dependence, 1831–1842
characteristics of substance abuse, 1141–1150
drugs
HIV in injecting drug users, 435–438
intervention for pregnant injectors, 1115–1125
nutrition on methadone maintenance, 1053–1061
smoking, brief interventions by midwives, 1715–1726

Young people
alcohol consumption, 1345–1357
Antenna research project into addiction, 1392#
predicting drink-driving behaviours, 1843–1857
see also Adolescents

Zimbabwe, adolescent alcohol use, 807–814
Zopiclone abuse, 285–286(L), 1389–1390(L)